The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.
Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions – Pharmaceutical Technology
Share this article Endocanninaboids are naturally occurring endogenous ligands that target cannabinoid receptors. Credit: Summit Art Creations via Shutterstock. Swiss company Synendos therapeutics has been